# A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.

> **NCT00333008** · PHASE2 · UNKNOWN · sponsor: **The Alvin and Lois Lapidus Cancer Institute** · enrollment: 27 (—)

## Conditions studied

- Diffuse Large B Cell Lymphoma
- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** Doxil
- **DRUG:** Cyclophosphamide
- **DRUG:** Vincristine
- **DRUG:** Prednisone
- **DRUG:** Rituximab
- **DRUG:** Pegfilgrastim

## Key facts

- **NCT ID:** NCT00333008
- **Lead sponsor:** The Alvin and Lois Lapidus Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-05
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 27 (—)
- **Last updated:** 2006-09-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00333008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00333008, "A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT00333008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*